A neoadjuvant treatment regimen of anti-PD-L1 monotherapy followed by anti-PD-L1 plus chemotherapy was well tolerated and led to a major pathologic response rate of 70% in patients with resectable gastric or gastroesophageal junction adenocarcinoma.

Comments

You must log in or register to comment.

(・_・;)

There's nothing here…

53 points (+53, −0)

Short URL:

http://blurb.social/158239

Health

Welcome to /f/health! This blurb is dedicated to all aspects of well-being. Join discussions on physical and mental health, nutrition, fitness, and medical advancements. Our rules: 1. Be respectful. 2. Stay on topic. 3. Provide reliable sources. 4. Avoid medical advice. 5. No self-diagnosis or promotion. Engage in informed discussions and explore the world of health with us!

Created June 22, 2023
Subscribe via RSS

Moderators

joeyrobert

See full list